Synopsys Q1 FY2026 revenue hits USD 2.4 billion, up 65.5%

Reuters
Feb 26
Synopsys Q1 FY2026 revenue hits USD 2.4 billion, up 65.5%

Synopsys reported Q1 FY2026 revenue of USD 2.409 billion (up 65.5%), with GAAP net income attributable to shareholders of USD 65.0 million and GAAP diluted EPS of USD 0.34. Non-GAAP net income was USD 718.5 million and non-GAAP diluted EPS was USD 3.77. Q1 segment revenue was USD 2.002 billion from Design Automation and USD 407.0 million from Design IP. Synopsys reiterated its FY2026 revenue outlook at a USD 9.61 billion midpoint, including USD 2.9 billion of expected Ansys revenue, and guided Q2 FY2026 revenue to USD 2.225 billion–USD 2.275 billion. The company’s board approved a replenishment of its stock repurchase program, authorizing up to USD 2.0 billion of common stock repurchases. Management commentary cited AI-driven demand for system-level and semiconductor R&D and increasing AI capabilities across its portfolio, and noted positioning to address engineering challenges “from silicon to systems.”

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Synopsys Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602251605PR_NEWS_USPR_____SF95131) on February 25, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10